Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Training experience across UK medicine: deanery differences versus site variation-General Medical Council National Training Survey 2025 analysis.

Frontiers in medicine·2026
Same author

Prevalence of Self-Reported Non-Coeliac Gluten Sensitivity and Its Association With Disorders of Gut-Brain Interaction and Disordered Eating.

United European gastroenterology journal·2026
Same author

European Society for the Study of Coeliac Disease (ESsCD) 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 2: Management, Follow-Up, and Complex Disease Courses.

United European gastroenterology journal·2026
Same author

Are we missing early pancreatic dysfunction? Expanding faecal elastase testing beyond pancreatic disease.

Current opinion in gastroenterology·2026
Same author

Factors Affecting Gluten-Free Dietary Adherence in Patients with Neurological Gluten-Related Disease.

Nutrients·2026
Same author

Long-term risk of acute pancreatitis in patients with celiac disease: A nationwide population-based cohort study.

Journal of internal medicine·2026

Related Experiment Video

Updated: Jul 1, 2026

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures
08:41

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures

Published on: December 27, 2024

Gluten ataxia.

Marios Hadjivassiliou1, David S Sanders, Nicola Woodroofe

  • 1Department of Neurology, The Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. m.hadjivassiliou@sheffield.ac.uk

Cerebellum (London, England)
|September 13, 2008
PubMed
Summary
This summary is machine-generated.

Gluten ataxia, an immune disorder from gluten, requires early diagnosis. Identifying antigliadin antibodies and IgA deposits aids in managing this condition and preventing progression.

More Related Videos

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
07:33

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

Published on: May 21, 2010

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Related Experiment Videos

Last Updated: Jul 1, 2026

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures
08:41

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures

Published on: December 27, 2024

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
07:33

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

Published on: May 21, 2010

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Area of Science:

  • Neurology
  • Immunology
  • Gastroenterology

Background:

  • Gluten ataxia is an immune-mediated neurological disorder.
  • It is triggered by gluten ingestion in susceptible individuals.
  • It presents as idiopathic sporadic ataxia.

Purpose of the Study:

  • To highlight gluten ataxia in the differential diagnosis of ataxia.
  • To emphasize the importance of early diagnosis and gluten-free diet.
  • To discuss reliable diagnostic markers for gluten ataxia.

Main Methods:

  • Review of clinical presentation and diagnostic markers.
  • Focus on antigliadin antibodies.
  • Analysis of IgA deposits against TG2 in the small bowel and extraintestinal sites.

Main Results:

  • Antigliadin antibodies are sensitive markers for gluten ataxia.
  • IgA deposits against TG2 are reliable and potentially more specific markers.
  • These markers may elucidate the pathogenesis of gluten sensitivity.

Conclusions:

  • Gluten ataxia should be considered in patients with idiopathic sporadic ataxia.
  • Early diagnosis and a gluten-free diet can improve symptoms and halt progression.
  • Antigliadin antibodies and TG2 IgA deposits are valuable diagnostic tools.